



Figure S1



Supplemental Figure 1: The *in vivo* effect of EPO on the expression of membrane-bound RANKL by bone marrow B cells. (A) Representative flow cytometry density plots demonstrating the expression of surface RANKL in bone marrow (BM) B cells (B220⁺CD19⁺ cells from diluent- or EPO-injected[†] female mice). Percent gated RANKL⁺B220⁺CD19⁺ cells are indicated. (B) Percent RANKL-expressing BM B cells (out of total B220⁺CD19⁺ cells). Graphs are mean ± SEM, n = 8-9 mice in each group. (C) EPO-R expression, as measured by RT-qPCR, in total BM (TBM) versus sorted total BM B cells (TBC, B220⁺CD19⁺) from either control diluent (TBM/TBC), or EPO-treated mice (TBM-EPO/TBC-EPO). Data are Mean ± SEM, > 6 mice in each group, *p* values were calculated by Student's *t*-test. * *p* < 0.05 versus TBM Control, #*p* < 0.05 versus B220⁺CD19⁺ control.

[†] EPO was administered for one week, as 3 injections of 180 U, administered every other day.


Figure S2



Supplemental Figure 2: Additional μ CT data of female mice carrying a conditional knockdown of EPO-R in the B cell lineage (MB1-Cre;EPO-R^{fl/fl})

Cortical bone: (A) Cortical thickness (Cort.Th) and (B) Bone area per total area (BA/TA). Trabecular bone: (C) trabecular bone volume (BV/TV); (D) Connectivity density (ConnD) and (E) Trabecular separation (Sp). Error bars represent 5-95 percentile range. n = 11 in each group. MB1-Cre;EPO-R^{wt/wt} were used as controls.

Figure S3



Supplemental Figure 3: Additional μ CT data describing the effect of EPO treatment on bone mass in MB1-Cre;EPO-R^{fl/fl} female mice as compared to genotypic controls

(A) Trabecular bone volume (BV/TV); (B) Trabecular number (Tb.N), (C) Connectivity density (Conn.D) and (D) total bone mineral density (BMD), as assessed by μ CT, in either EPO- or diluent (DIL)-treated MB1-Cre;EPO-R^{fl/fl} versus control mice. Error bars represent 5-95 percentile. n = 9-10 in each group. MB1-Cre;EPO-R^{wt/wt} were used as genotypic controls.